TouretteSyndrome Treatment Market, by Drug Class (Antiadrenergic Agents,Antipsychotic Agents, Atypical Antipsychotics, Carbonic Anhydrase InhibitorAnticonvulsants, Others), by Distribution Channel (Hospital Pharmacies, RetailPharmacies, and Online Pharmacies), and by Region (North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook,and Opportunity Analysis, 2019 – 2026
Tourette syndrome is a rare andsevere neurological disorder which causes tics. Tic is a repetitive involuntarymovements, sudden, no rhythmic motor movements. It occurs due to the mutations ofthe SLITRK1 gene, which plays an important role in development of nerve cells.This syndrome usually occurs among the people of age between 2-15 years. Thereare four types of tics: motor tics (uncontrolled body movements), vocal tics(outburst of sound), simple tics (includes few parts of body) and complex tics(contains several parts of body). Tourette’s syndrome is related to otheradditional neurobehavioral problems like impulsivity, problems with reading andwriting, obsessive compulsive symptoms. It can be treated with neuroleptics;haloperidol and pimozide are largely used medicines for Tourette syndrome.Other medications such as guanfacine and clonidine are useful to treat theseverity of tics.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2642
Tourette Syndrome TreatmentMarket Drivers
Drug approvals by regulatoryauthorities is expected to boost the global tourette syndrome treatment marketgrowth. For instance, in October 23, 2017, Neurocrine Biosciences Inc.announced that the Food Drug and Administration approved valbenazine orphandrug designation to treat the pediatric patients with the Tourette syndrome.Furthermore, in September 19, 2017, Teva Pharmaceutical Industries andNuvelution Pharma announced their partnership to develop AUSTEDO(deutetrabenazine) tablets for the treatment of tics which is associated totourette syndrome in pediatric patients in the U.S. This partnership will drivethe development of Austedo (deutetrabenazine) in Tourette syndrome by bringingnew treatment options more quickly which are more necessary for the affectedyoung patients. These factors are expected to propel the global Tourette syndrometreatment market growth.
Moreover, there are severalinvestigations made for the treatment of Tourette syndrome. For instance, inMarch 2019, Wesley Medical Research was partnering with the University ofSydney in Australia which carried the clinical trial to investigate whether themedical cannabis could be used to treat the individuals with Tourette syndrome.This trial will help examine efficacy and safety of cannabinoids on ticfrequency as well as the psychiatric symptoms associated with Tourettesyndrome.
Furthermore, the acquisitions ofcompanies drive the growth of the Tourette syndrome treatment market. Forinstance, on August 14, 2018, Emalex Biosciences acquired the PsyadonPharmaceuticals and the rights to develop, register and market ecopipam, theinvestigational drug of Psyadon Pharmaceuticals, which is used to treat theTourette syndrome in children less than 16 years of age.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/tourette-syndrome-treatment-market-2642
Tourette Syndrome Treatment MarketRegional Analysis
On the basis of region, theTourette syndrome market is segmented into North America, Latin America,Europe, Asia Pacific, Middle East, and Africa. North America is expected tohold a dominant position in the Tourette syndrome treatment market due topresence of large number of key players like Otsuka Holdings Co., Ltd,AstraZeneca PLC, Catalyst Pharmaceutical Parteners, Inc. In terms of revenue,U.S. contributes the major share of this syndrome treatment market. Accordingto the National Institute Of Neurological Disorders And Stroke(NIH), it isestimated that around 2,00,000 Americans have the most severe form of Tourettesyndrome and as many as one in 100 shows milder or less complex symptoms suchas vocal tics.
Tourette Syndrome TreatmentMarket Restraints
Withdrawal of the drugs in latestages of clinical trials has hampered the global Tourette syndrome treatmentmarket growth. For instance, on December 12, 2018, Neurocrine Biosciencesrevealed that the phase IIb study of valbenazine did not meet the primaryendpoint of reducing the tic severity in young people in moderate to severeform of diseases.
Tourette Syndrome TreatmentMarket Key Players
Some of the major playersoperating in the global Tourette syndrome treatment market include NeurocrineBiosciences Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Apotex, Inc.,Janssen Pharmaceuticals, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals,Torrent Pharmaceuticals Limited and Eli Lilly Pharmaceuticals.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2642
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
